OR WAIT null SECS
August 21, 2026
Article
A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.
August 17, 2026
Video
Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.
August 12, 2026
In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the commercial release of insulin icodec.
August 11, 2026
In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.
Podcast
Once-weekly insulin icodec hits US pharmacies, simplifying basal dosing for type 2 diabetes with new titration rules and promising A1c results.
Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.
August 10, 2026
Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.
August 09, 2026
In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.
August 07, 2026
The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.
August 06, 2026
Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.
